CAC2 Childhood Cancer Community News Digest (January 10-23)
Assorted news from the last two weeks:
Adolescents and young adult cancer survivors are more likely to have psychological distress and additional annual medical expenses than adults with no history of cancer, according to a study published in Cancer.
The FDA has granted both Rare Pediatric Disease Designation and Orphan Drug Designation Lantern Pharma’s drug candidate LP-184 for the treatment of pediatric patients with ATRT.
Two anti-cancer antibodies have a much stronger effect against pediatric nerve-cell and bone cancers in mice than either one alone, researchers have discovered.
The Spanish perspective: The future of pediatric oncology lies in precision medicine.
An answer to the question of why Ondansetron, a 5-HT3 receptor agonist that is widely used to manage chemotherapy-induced nausea and vomiting (CINV), seems to work better for some pediatric patients with cancer who experience CINV but not others.
The COVID-19 pandemic is having a profound impact on pediatric oncology health care providers (HCPs), according to a study published online Jan. 24 in Cancer.
Upcoming Webinars and Online Opportunities:
CAC2 member Mark Levine hosts a podcast called, “Help and Hope Happen Here” (available on Apple Podcasts, Spotify, and Google Podcasts). Access recent podcasts with CAC2 Members (and visit Help and Hope Happen Here for interviews with other CAC2 members and thought leaders from around the community):
- Juanita Prada (Survivor and Advocate)
- Pat Lacey (Beat Childhood Cancer)
- Stan Robbins (Advocate)
- Blog Posts (65)
- Guest Blogs (18)
- Member Blogs (24)
- Survivorship Matters Blog (9)
- CAC2 News (21)
- Collaborative Achievements (13)
- Community News (170)
- News Digest (130)
- Research Explained (10)
- Webinars (61)